A promising trial of Bristol-Myers Squibb's investigational attachment inhibitor GS-663068 raises hope of the introduction of a new antiretroviral drug class, which would especially benefit those with multidrug resistance, aidsmap reports.
http://ift.tt/PUpRcr
http://ift.tt/PUpRcr
No comments:
Post a Comment